Bicocca Open Archive

Logo unimib boa
POGLIANI, ENRICO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.422
AS - Asia 5.912
EU - Europa 5.196
SA - Sud America 969
AF - Africa 157
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 11
Totale 24.683
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.902
SG - Singapore 2.131
CN - Cina 1.392
HK - Hong Kong 943
IT - Italia 922
DE - Germania 808
RU - Federazione Russa 748
BR - Brasile 725
SE - Svezia 638
IE - Irlanda 614
VN - Vietnam 581
UA - Ucraina 559
CA - Canada 440
GB - Regno Unito 261
FR - Francia 202
IN - India 197
FI - Finlandia 140
KR - Corea 115
BD - Bangladesh 111
AR - Argentina 81
IQ - Iraq 63
JP - Giappone 59
TR - Turchia 58
NL - Olanda 55
ZA - Sudafrica 54
EC - Ecuador 50
PK - Pakistan 43
AT - Austria 42
MX - Messico 42
ES - Italia 41
PL - Polonia 35
DK - Danimarca 34
ID - Indonesia 31
SA - Arabia Saudita 31
CO - Colombia 30
BE - Belgio 29
PH - Filippine 25
VE - Venezuela 23
MA - Marocco 19
UZ - Uzbekistan 19
CL - Cile 18
EG - Egitto 18
PY - Paraguay 17
ET - Etiopia 14
EU - Europa 14
TN - Tunisia 14
KE - Kenya 13
LT - Lituania 12
MY - Malesia 12
UY - Uruguay 11
AE - Emirati Arabi Uniti 10
DO - Repubblica Dominicana 10
BG - Bulgaria 9
NP - Nepal 9
AU - Australia 8
OM - Oman 8
PE - Perù 8
RO - Romania 8
TH - Thailandia 8
AZ - Azerbaigian 7
DZ - Algeria 7
PS - Palestinian Territory 7
JM - Giamaica 6
JO - Giordania 6
KZ - Kazakistan 6
CZ - Repubblica Ceca 5
IL - Israele 5
LB - Libano 5
AL - Albania 4
BH - Bahrain 4
HU - Ungheria 4
IR - Iran 4
PA - Panama 4
PT - Portogallo 4
RS - Serbia 4
TW - Taiwan 4
BO - Bolivia 3
BY - Bielorussia 3
CR - Costa Rica 3
HR - Croazia 3
KH - Cambogia 3
LK - Sri Lanka 3
MK - Macedonia 3
NI - Nicaragua 3
SN - Senegal 3
AM - Armenia 2
BW - Botswana 2
CH - Svizzera 2
CI - Costa d'Avorio 2
GA - Gabon 2
GT - Guatemala 2
HN - Honduras 2
KG - Kirghizistan 2
KW - Kuwait 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
SI - Slovenia 2
SR - Suriname 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
Totale 24.657
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.839
Ashburn 1.187
Singapore 1.125
Woodbridge 1.039
Hong Kong 925
Houston 753
Fairfield 647
San Jose 628
Dublin 600
Jacksonville 591
Chandler 457
Frankfurt am Main 400
Wilmington 373
Dearborn 323
New York 307
Milan 285
Seattle 258
Toronto 241
Princeton 226
Beijing 211
Cambridge 207
Los Angeles 184
Chicago 183
Ho Chi Minh City 175
Santa Clara 148
Hanoi 143
Hefei 142
The Dalles 133
Nanjing 129
Shanghai 126
Seoul 108
Lawrence 103
Lachine 102
Altamura 100
Dallas 98
Lauterbourg 98
Buffalo 78
Moscow 77
São Paulo 69
Rome 60
Göttingen 52
Boardman 47
Council Bluffs 45
Guangzhou 44
Nanchang 42
Changsha 40
Tokyo 39
Andover 37
San Diego 35
Vienna 33
London 32
Shenyang 32
Orem 31
Brussels 29
Ottawa 29
Hebei 28
Montreal 27
Munich 27
Warsaw 27
Rio de Janeiro 26
Atlanta 25
Helsinki 25
Haiphong 24
Johannesburg 24
Baghdad 22
Brooklyn 22
Huizen 22
Denver 20
Tampa 20
Salt Lake City 19
Fremont 18
Fürstenwalde 18
Guayaquil 18
Jiaxing 18
Jinan 18
Tianjin 18
Chennai 17
Da Nang 17
Hangzhou 17
Lahore 17
Lissone 17
Manchester 17
Pune 17
Tashkent 17
Dhaka 16
Norwalk 16
Redmond 16
Zhengzhou 16
Jeddah 15
New Delhi 15
Nürnberg 15
University Park 15
Bologna 14
Boston 14
Figino 14
Mumbai 14
Kunming 13
Mountain View 13
Poplar 13
Addis Ababa 12
Totale 16.278
Salva come PNG Salva come JPEG
Nome #
Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease 566
Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients 486
A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia 458
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 447
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 427
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 410
GMP-grade preparation of biomimetic scaffolds with osteo-differentiated autologous mesenchymal stromal cells for the treatment of alveolar bone resorption in periodontal disease 405
A boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation 382
Imatinib long term effects study: three years of follow-up and assessment 373
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 372
Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients 353
Thrombosis of the splenoportal axis after splenectomy 351
A CASE OF ATYPICAL PROLONGED HEMATOLOGIC TOXICITY WITH AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), REVIEW OF LITERATURE AND A PROPOSAL OF MANAGEMENT 310
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 307
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 302
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study 300
Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146(+) immunomagnetic enrichment-flow cytometry and soluble E-selectin detection 291
Development of polycythemia vera after chemotherapy-induced remission of acute myeloid leukemia: a case report 286
Severe, reversible nelarabine-induced neuropathy and myelopathy 286
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 283
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 282
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 279
A prospective study on cardiovascular events after acute pulmonary embolism 272
Combined prophylactic low-molecular weight heparin and low dose aspirin reduces the occurrences of adverse pregnancy outcome in multiparous women with preeclampsia and intrauterine fetal growth restriction in antecedent pregnancy 267
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 265
A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study) 264
CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease 264
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies 263
Recurrent preeclapsia: The role of acquired and heritable thrombophilia 259
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 256
Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma 256
Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy 250
Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination 250
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 247
Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy 244
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 243
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 242
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 239
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 238
Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: A case report 236
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect 232
NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma 232
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study 229
Autoimmune hepatitis presenting as imatinib toxicity: description of a case and of therapeutic alternatives 228
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) 227
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance 227
Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone 223
Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect? 220
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients 219
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group 216
High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: A randomized study 214
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 213
Atypical presentation of Upshaw-Schulman syndrome in a pregnant patient homozygous for V Leiden mutation 212
Platelet activation during plasma-reduced multicomponent PLT collection: A comparison between COBE Trima and Spectra LRS turbo cell separators 210
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 209
Frozen-and-thawed allogeneic platelet gels for treating postoperative chronic wounds 208
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients 206
Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease 204
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial 203
Crizotinib in anaplastic large-cell lymphoma 202
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies 198
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) 198
Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 195
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00 190
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation 190
CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 189
Reviewed diagnosis of primary and secondary immune thrombocytopenic purpura in 79 adult patients hospitalized in 2000 - 2002 188
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia 182
Development of c-Kit-expressing Small-Cell lung Cancer in a Chronic Myeloid Leukemia Patient During Imatinib Treatment 180
Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature 180
SIGNIFICANT REDUCTION IN FASTING BLOOD GLUCOSE IN NONDIABETIC PH+ CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB MESYLATE 180
A case of Philadelphia Positive Acute Lymphoblastic Leukaemia with three different phenotypic lineage, each one presenting the same BCR-ABL hybrid transcript 178
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 178
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 176
HOMOZYGOSITY FOR JAK2V617F IDENTIFIES MPD PATIENTS WITH A MORE SYMPTOMATIC DISEASE A RETROSPECTIVE STUDY ON 989 PATIENTS FROM THE GIMEMA-MPD WORKING PARTY 174
Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials 173
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenström's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: Proposal for a common prognostic scoring system 172
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 169
From Vaquez to Dameshek through JAK…2 much for polycythemia vera to be feared? 168
Low Efficiency of a Newly Introduced High-Density Microparticles Method for B Cell Depletion in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation 168
Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program 166
Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD 166
Advanced mast cell disease: an Italian Hematological Multicenter experience 165
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia 164
Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells 163
Imatinib concentrations in human milk 163
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 163
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 163
Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response 158
Management of poor peripheral blood stem cell mobilization: Incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions 155
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients 153
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate 151
Corticosteroids can reverse severe imatinib-induced hepatotoxicity 151
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 151
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 149
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome 149
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' [2] 147
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia 143
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study 142
Mast cell leukemia: A report of ten cases 142
Totale 23.575
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.009
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.009
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202185 0 0 0 0 0 0 0 0 0 0 0 85
2021/20221.088 50 58 90 111 85 103 42 85 71 92 106 195
2022/20232.038 293 671 195 163 127 311 17 79 109 6 34 33
2023/20241.665 38 45 54 78 244 490 341 47 174 13 21 120
2024/20253.085 211 356 120 138 296 75 122 75 319 462 312 599
2025/20268.467 764 566 669 953 969 455 1.212 449 687 740 377 626
Totale 25.005